Ruixun Biotech is a healthcare company that specializes in biotechnology, aiming to merge innovation and precision to advance molecular diagnosis and genetic testing. Founded in 2017, the company integrates microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to develop upstream equipment and consumables for molecular diagnosis and genetic testing. Its product lineup includes the digital PCR apparatus DropX-2000 and over 50 different RUO detection kits.
The latest milestone for Ruixun Biotech was the Series C investment at 17 November 2022, with funding from Kaitai Capital and Qiandao Fund. With a focus on advancing healthcare through cutting-edge biotechnology, Ruixun Biotech presents a promising venture for investors seeking opportunities in the Biotechnology and Health Care industries.
